Who is sponsoring NCT00015704?

NCT00015704 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00015704 study?

NCT00015704 studies HIV Infections.

What is the status of NCT00015704?

NCT00015704 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

An Open-Label, Pilot Study Utilizing CD4 T-Cell Counts Lower Than 350 Cells/mm3 as the Threshold for Restarting Therapy With Potent Antiretroviral Therapy With or Without Interleukin-2 to Determine the Effect of Pulse Therapy on the Characteristics of Treatment Interruptions

NCT00015704 NA COMPLETED

Interleukin-2 (IL-2) helps the body make infection-fighting white blood cells, including CD4 and CD8 T cells. One HIV treatment strategy is planned treatment interruption (stopping anti-HIV drugs when CD4 count and level of virus in the blood are at certain levels). The purpose of this study is to see if IL-2 used with potent anti-HIV drugs allows for longer HIV treatment interruptions.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	NA
Status	COMPLETED
Enrolment	80
Completion	2004-11

Conditions

HIV Infections

Interventions

Aldesleukin

Countries

United States